Substituted pyrrolidine and related compounds

Details Substituted pyrrolidine and related compounds Substituted pyrrolidine and related compounds

2008-04-01

2008-04-01

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S184000, C546S246000, C546S247000, C548S566000, C548S567000, C548S568000, C514S408000, C514S428000

Reexamination Certificate

active

11602802

ABSTRACT:
This invention is directed to compounds of formula I:wherein R1-R5and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.

REFERENCES:
patent: 3192206 (1965-06-01), Lunsford et al.
patent: 3192210 (1965-06-01), Lunsford et al.
patent: 3192221 (1965-06-01), Lunsford et al.
patent: 3247222 (1966-04-01), Lunsford
patent: 3732247 (1973-05-01), Helsley et al.
patent: 3984557 (1976-10-01), Welstead, Jr.
patent: 4002766 (1977-01-01), Welstead, Jr.
patent: 4594343 (1986-06-01), Shanklin, Jr.
patent: 4810713 (1989-03-01), Yanni et al.
patent: 4950674 (1990-08-01), Yanni et al.
patent: 5070087 (1991-12-01), Teng et al.
patent: 5096890 (1992-03-01), Cross et al.
patent: 5233053 (1993-08-01), Cross et al.
patent: 5340831 (1994-08-01), Cross et al.
patent: 5344835 (1994-09-01), Alker et al.
patent: 5486527 (1996-01-01), Alker et al.
patent: 5607950 (1997-03-01), Alker et al.
patent: 5750540 (1998-05-01), Tsuchiya et al.
patent: 5932594 (1999-08-01), Cross et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6403810 (2002-06-01), Klaus et al.
patent: 6433027 (2002-08-01), Bozung et al.
patent: 6693202 (2004-02-01), Aggen et al.
patent: 7183292 (2007-02-01), Mammen et al.
patent: 2003/0018019 (2003-01-01), Meade et al.
patent: 2004/0122014 (2004-06-01), Mammen et al.
patent: 2005/0026954 (2005-02-01), Mammen et al.
patent: 2005/0113413 (2005-05-01), Wilson et al.
patent: 0 178 946 (1986-04-01), None
patent: 0 178 947 (1986-04-01), None
patent: 0 235 463 (1987-09-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 999 205 (2000-05-01), None
patent: 1 020 499 (2000-07-01), None
patent: 4-90559 (1992-03-01), None
patent: 4-151168 (1992-05-01), None
patent: 11 100366 (1999-04-01), None
patent: WO 91/09013 (1991-06-01), None
patent: WO 98/54167 (1998-12-01), None
patent: WO 99/64043 (1999-12-01), None
patent: WO 2004/041806 (2004-05-01), None
patent: WO 2004/089892 (2004-10-01), None
Broadley et al., “Muscarinic Receptor Agonists and Antagonists”, Molecules, 6, pp. 142-193 (2001).
Cale et al., “A Series of Central Nervous System Stimulants Based on the 4-Substituted 3,3-Diphenyl-2-pyrrolidinone Skeleton. II”, J. Med. Chem., 10(2), pp. 214-222 (1967).
Eglen et al., “Muscarinic Receptor Subtypes:Pharmacology and Therapeutic Potential”, DN&P, 10(8), pp. 462-469 (1997).
Graul et al., “Darifenacin”, Drugs of the Future, 21(11), pp. 1105-1108 (1996).
Taniguchi et al., “Agents for the Treatment of Overactive Detrusor, VI.1a)Synthesis and Pharmacological Properties of Acetamide Derivatives Bearing Cyclic Amines inN-Substituents”, Chem. Pharm. Bull, 42(1), pp. 74-84) 1994.
Zlotos et al., “Muscarinic receptor agonists and antagonists”, Exp. Opin. Ther. Patents, 9(8), pp. 1029-1053 (1999).
Yeh, et al., “Molecular and Structural Basis of Resting and Use-Dependent Block of Sodium Current Defined Using Disopyramide Analogues”, Biophys. J., vol. 51, pp. 123-135 (1987).

Affiliated with

Also associated with

Rating

Substituted pyrrolidine and related compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted pyrrolidine and related compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrrolidine and related compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3926907